RGC — Regencell Bioscience Holdings Limited stock price, charts and financials
QT10Regencell Bioscience Holdings LimitedRegencell Bioscience Holdings Limited (NASDAQ: RGC) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
5.79
-0.17-2.85%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 10.93% | Shs Outstand | 495.47M | Perf Week | 2.66% |
| Market Cap | 2.87B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 17.28M | Perf Month | -0.34% |
| Enterprise Value | 2.87B | PEG | 4.21 | EPS next Q | - | Inst Own | - | Short Float | 0.19% | Perf Quarter | -51.79% |
| Income | -7.17M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 3.15 | Perf Half Y | -78.56% |
| Sales | 0.00 | P/B | - | EPS next Y | - | ROA | -233.91% | Short Interest | 951.70K | Perf YTD | -72.43% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -231.87% | 52W High | 69.01 -91.61% | Perf Year | -62.88% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -444.21% | 52W Low | 4.51 28.38% | Perf 3Y | 1377.64% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.13% 8.14% | Perf 5Y | 735.62% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -114.94% | Oper. Margin | 0.00% | ATR (14) | 0.53 | Perf 10Y | - |
| Dividend Ex-Date | Feb 15, 2018 | Quick Ratio | 1.42 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 47.42 | Recom | 3.00 |
| Dividend Gr. 3/5Y | -37.00% -23.51% | Current Ratio | 1.42 | EPS Q/Q | - | SMA20 | -0.22% | Beta | 1.27 | Target Price | - |
| Payout | 0.00% | Debt/Eq | 0.32 | Sales Q/Q | - | SMA50 | 2.42% | Rel Volume | 0.29 | Prev Close | 5.96 |
| Employees | 10 | LT Debt/Eq | - | Earnings | Oct 28 | SMA200 | -70.51% | Avg Volume | 320.99K | Price | 5.79 |
| IPO Date | Jul 16, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | - | Net Debt/EBITDA | 0.28 | Volume | 94,032 | Change | -2.85% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jan-02-18 | Downgrade | B. Riley | Buy → Neutral | |
| Dec-06-17 | Downgrade | Macquarie | Outperform → Neutral | |
| Dec-06-17 | Downgrade | RBC Capital | Outperform → Perform | |
| Dec-06-17 | Upgrade | Moffett Nathanson | Sell → Neutral |
Latest News· Times ET
Aug-18-26
Aug-18-2602:53PM
Aug-07-26
Aug-05-26
Jul-14-26
Jul-14-2608:38AM
Jul-08-26
Jul-06-26
04:45AM
Jun-29-26
Jun-26-26
Company
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 6/30/2025 | FY 2024 6/30/2024 | FY 2023 6/30/2023 | FY 2022 6/30/2022 | FY 2021 6/30/2021 | FY 2020 6/30/2020 | FY 2019 6/30/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 1 | 1 | — | — | — | — | |
| Gross Profit | 0 | -1 | -1 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 2 | 3 | 5 | — | — | — | — | |
| Research and Development | 1 | 1 | 2 | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -1 | — | — | — | — | |
| Operating Income | -4 | -5 | -6 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 0 | 0 | — | — | — | — | |
| Net Income Before Taxes | -4 | -4 | -6 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -4 | -4 | -6 | — | — | — | — | |
| Net Income From Continuing Operations | -4 | -4 | -6 | — | — | — | — | |
| Net Income | -4 | -4 | -6 | — | — | — | — | |
| EPS (Recurring) | -0.01 | -0.01 | -0.01 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.01 | -0.01 | -0.01 | — | — | — | — | |
| EPS (Diluted) | -0.01 | -0.01 | -0.01 | — | — | — | — | |
| EBITDA | -3 | -4 | -5 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 494 | 494 | 494 | — | — | — | — | |
| Market Capitalization | 8,418 | 44 | 300 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BELL THOMAS D JR | Director | Aug 29 '17 | Buy | 14.76 | 25,000 | 369,000 | 126,939 | Aug 29 |
| KAPLAN STEPHEN A | Director | Aug 25 '17 | Buy | 14.87 | 10,000 | 148,700 | 155,572 | Aug 28 |
| Ownby David | EVP, CFO and Treasurer | Aug 24 '17 | Buy | 14.04 | 7,500 | 105,300 | 229,573 | Aug 24 |
| DUNN GREGORY W | President and COO | Mar 09 '17 | Sale | 22.15 | 26,050 | 577,008 | 67,052 | Mar 10 |
| BRANDOW PETER B | EVP, General Counsel, Sec. | Mar 09 '17 | Sale | 22.50 | 20,233 | 455,243 | 212,715 | Mar 10 |
| ANSCHUTZ PHILIP F | 10% Owner | Nov 23 '16 | Sale | 22.95 | 13,000,000 | 298,350,000 | 0 | Nov 23 |
| DUNN GREGORY W | President and COO | Sep 07 '16 | Sale | 21.75 | 30,765 | 669,139 | 74,151 | Sep 08 |
| ANSCHUTZ PHILIP F | 10% Owner | Aug 08 '16 | Sale | 21.60 | 13,000,000 | 280,800,000 | 0 | Aug 08 |
| BRANDOW PETER B | EVP, General Counsel, Sec. | Jun 29 '16 | Sale | 21.51 | 49,024 | 1,054,506 | 219,028 | Jun 29 |
| DUNN GREGORY W | President and COO | Jun 15 '16 | Sale | 20.28 | 25,000 | 507,000 | 104,916 | Jun 17 |
| MILES AMY E | CEO | Mar 15 '16 | Sale | 20.82 | 28,201 | 587,145 | 588,405 | Mar 16 |
| MILES AMY E | CEO | Mar 14 '16 | Sale | 21.22 | 75,000 | 1,591,500 | 616,606 | Mar 16 |
| DUNN GREGORY W | President and COO | May 19 '15 | Sale | 21.40 | 19,000 | 406,600 | 109,724 | May 20 |
| Weigand Nestor R Jr | Director | Mar 13 '15 | Buy | 22.54 | 88 | 1,987 | 52,837 | Apr 13 |
| YEMENIDJIAN ALEX | Director | Feb 18 '15 | Sale | 23.37 | 58,475 | 1,366,548 | 5,241 | Feb 19 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.